Compare HCAT & CDXS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | HCAT | CDXS |
|---|---|---|
| Founded | 2008 | 2002 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Computer Software: Programming Data Processing | Major Chemicals |
| Sector | Technology | Industrials |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 174.0M | 141.8M |
| IPO Year | 2019 | 2010 |
| Metric | HCAT | CDXS |
|---|---|---|
| Price | $2.72 | $1.69 |
| Analyst Decision | Hold | |
| Analyst Count | 11 | 0 |
| Target Price | ★ $4.30 | N/A |
| AVG Volume (30 Days) | 858.1K | ★ 1.5M |
| Earning Date | 11-10-2025 | 11-06-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $316,063,000.00 | $52,932,000.00 |
| Revenue This Year | $3.23 | $12.88 |
| Revenue Next Year | N/A | $21.64 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 4.63 | N/A |
| 52 Week Low | $2.02 | $1.52 |
| 52 Week High | $8.91 | $6.08 |
| Indicator | HCAT | CDXS |
|---|---|---|
| Relative Strength Index (RSI) | 49.60 | 38.96 |
| Support Level | $2.02 | $1.62 |
| Resistance Level | $3.03 | $1.79 |
| Average True Range (ATR) | 0.23 | 0.12 |
| MACD | 0.06 | 0.03 |
| Stochastic Oscillator | 69.80 | 42.50 |
Health Catalyst Inc provides data and analytics technology and services to healthcare organizations. It has two operating segments. The Technology segment, the key revenue driver, includes data platforms, analytics applications, and support services. This generates revenues mainly from contracts that are cloud-based subscription arrangements, time-based license arrangements, and maintenance and support fees; the Professional Services segment is generally the combination of analytics, implementation, strategic advisory, outsourcing, and improvement services to deliver expertise to its customers to more fully configure and utilize the benefits of the technology offerings.
Codexis Inc is a provider of enzymatic solutions for efficient and scalable therapeutics manufacturing that leverages its proprietary CodeEvolver technology platform to discover, develop, and enhance novel, high-performance enzymes. Codexis enzymes solve challenges associated with small molecule pharmaceuticals manufacturing and nucleic acid synthesis. The Company is currently developing its proprietary ECO Synthesis manufacturing platform to enable the scaled manufacture of RNAi therapeutics through an enzymatic route. Codexis' enzymes can drive improvements such as higher yields, reduced energy usage and waste generation, improved efficiency in manufacturing and greater sensitivity in genomic and diagnostic applications. Geographically, it derives maximum revenue from the Americas.